Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EPO Ceasefire? Amgen Aranesp Price To Remain Stable Unless J&J Acts First

Executive Summary

Amgen does not intend to continue implementing Aranesp price discounts unless J&J moves first, Amgen Exec VP-Global Commercial Operations George Morrow said during an earnings call April 22

You may also be interested in...



Amgen Expects Stable Aranesp Pricing Despite J&J Lawsuit Over Rebates

Amgen anticipates pricing for its anemia therapy Aranesp (darbepoetin) to be stable regardless of the outcome of a lawsuit by Johnson & Johnson challenging its discounting practices

Amgen Expects Stable Aranesp Pricing Despite J&J Lawsuit Over Rebates

Amgen anticipates pricing for its anemia therapy Aranesp (darbepoetin) to be stable regardless of the outcome of a lawsuit by Johnson & Johnson challenging its discounting practices

Aranesp Growth Tied To Market Penetration, Not Share Gains, Amgen Says

Amgen expects future Aranesp growth to come from greater market penetration rather than market share gains as a result of the shift to average sales price-based reimbursement under Medicare Part B

Related Content

UsernamePublicRestriction

Register

PS043854

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel